

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Renal damage in primary aldosteronism: a systematic review and meta-analysis

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1725903> since 2023-04-04T14:12:50Z

*Published version:*

DOI:10.1097/HJH.0000000000002216

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

## ONLINE SUPPLEMENT

### Renal damage in primary aldosteronism: a systematic review and meta-analysis

Silvia Monticone, Elisa Sconfienza, Fabrizio D'Ascenzo, Fabrizio Buffolo, Fumitoshi Satoh, Leonardo A. Sechi, Franco Veglio, Paolo Mulatero

#### Supplementary methods

#### Supplementary references

#### Reference list of included studies

**Table S1.** Parameters chosen for clinical matching of patients affected by PA with non-PA hypertensive patients across the studies.

**Table S2.** Clinical and biochemical parameters of the included patients.

**Table S3.** Criteria adopted to evaluate GFR across the included studies.

**Figure S1.** Forest plot of serum creatinine ( $\mu\text{mol/L}$ ) in patients affected by PA and non-PA hypertensive patients.

**Figure S2.** Forest plot of albuminuria in patients affected by PA and patients affected by non-PA hypertensive patients.

**Figure S3.** Forest plot of the odds ratio of microalbuminuria in patients with PA and non-PA hypertensive patients.

**Figure S4.** Forest plot of the odds ratio of proteinuria in patients with PA and non-PA hypertensive patients.

**Figure S5.** Forest plot of uAC ratio in patients with PA and non-PA hypertensive patients.

**Figure S6.** Funnel plot analysis for serum creatinine in patients affected by PA compared with non-PA hypertensive patients.

**Figure S7.** Funnel plot analysis for GFR in patients affected by PA compared with non-PA hypertensive patients.

**Figure S8.** Funnel plot analysis for quantitative albuminuria in patients affected by PA compared with non-PA hypertensive patients.

**Figure S9.** Funnel plot analysis for uAC ratio in patients affected by PA compared with hypertensive non-PA patients.

**Figure S10.** Meta-regression analysis for the prevalence of diabetes on mean difference in GFR between patients affected by PA and non-PA patients.

**Figure S11.** Meta-regression analysis for duration of hypertension on mean difference in GFR between patients affected by PA and non-PA patients.

**Figure S12.** Forest plot of serum creatinine in patients affected by PA before and after specific treatment

**Figure S13.** Forest plot of uACR in patients affected by PA before and after specific treatment (either adrenalectomy or medical treatment).

**Figure S14.** Qualitative evaluation of studies.







\$SHU72 \$UFKLYLR ,VWLWX]LRQDOH 2SHQ \$FFHV V GHOO 8QLY

5HQDO GDPDJH LQ SULPDU\ DOGRVWHURQLVP D V\ VWHPDWLF UHYLHZ DQG P

7KLV LV D SUH SULQW YHUVLRQ RI WKH IROORZLQJ DUWLFOH

Original Citation:

Availability:

7KLV YHUVLRQ LKWDWSLODEOHKDQGOH QHW VLQFH 7 =

Published version:

DOI:10.1097/HJH.0000000000002216

Terms of use:

Open Access

\$Q\ RQH FDQ IUHHO\ DFFHV V WKH IXOO WH[W RI ZRUNV PDGH DYDLODEOH D  
XQGHU D &UHDWLYH &RPPRQV OLFHQVH FDQ EH XVHG DFFRUGLQJ WR WKH  
RI DOO RWKHU ZRUNV UHTXLUHV FRQVHQW RI WKH ULJKW KROGHU DXWKR  
SURWHFWLRQ E\ WKH DSSOLFDEOH ODZ

(Article begins on next page)

- Park KS, Kim JH, Yang YS, Hong AR, Lee DH, Moon MK, Choi SH, Shin CS, Kim SW, Kim SY. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism. *Endocr J.* 2017; 64:623-632.

**Pilz S., 2014**

- Pilz S, Kienreich K, Gaksch M, Grübler M, Verheyen N, Bersuch LA, Schmid J, Drechsler C, Ritz E, Moosbrugger A, Stepan V, Pieber TR, Meinitzer A, März W, Tomaschitz A. Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading. *Horm Metab Res.* 2014; 46:427-432.

**Pimenta E., 2011 (1)**

- Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, Stowasser M. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. *J Clin Endocrinol Metab.* 2011; 96:2813-2820.

**Pimenta E., 2011 (2)**

- Pimenta E, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma. *J Hum Hypertens.* 2011; 25:592-599.

**Reincke M., 2009**

- Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S; Participants of German Conn's Registry. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. *J Clin Endocrinol Metab.* 2009; 94:869-875.

**Ribstein J., 2005**

- Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. *J Am Soc Nephrol.* 2005; 16:1320-1325.

**Rosa J., 2012**

- Rosa J, Somlóová Z, Petrák O, Strauch B, Indra T, Senitko M, Zelinka T, Holaj R, Widimský J Jr. Peripheral arterial stiffness in primary aldosteronism. *Physiol Res.* 2012; 61:461-468.

**Rossi G.P., 2006**

- Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. *Hypertension.* 2006; 48:232-238.

**Savard S., 2013**

- Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension* 2013; 62:331-336.

**Sechi L.A., 2006**

- Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. *JAMA* 2006; 295:2638-2645.

**Sechi L.A., 2009**

- Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. *J Clin Endocrinol Metab.* 2009; 94:1191-1197.

**Somloova Z., 2010**

- Somlóová Z, Widimský J Jr, Rosa J, Wichterle D, Strauch B, Petrák O, Zelinka T, Vlková J, Masek M, Dvoráková J, Holaj R. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. *J Hum Hypertens.* 2010; 24:625-630.

**Takeda R., 1995**

- Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. *J Endocrinol Invest.* 1995; 18:370-373.

**Tanase-Nakao K., 2014**

- Tanase-Nakao K, Naruse M, Nanba K, Tsuiki M, Tagami T, Usui T, Okuno H, Shimatsu A, Hashimoto S, Katabami T, Ogo A, Okumura A, Umakoshi H, Suzuki T. Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism. *Clin Endocrinol (Oxf).* 2014; 81:665-670.

**Turchi F., 2013**

- Turchi F, Ronconi V, di Tizio V, Ceccoli L, Boscaro M, Giacchetti G. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. *Nutr Metab Cardiovasc Dis.* 2014; 24:476-482.

**Utsumi T., 2017**

- Utsumi T, Kamiya N, Kaga M, Endo T, Yano M, Kamijima S, Kawamura K, Imamoto T, Ichikawa T, Suzuki H. Development of novel nomograms to predict renal functional outcomes after laparoscopic adrenalectomy in patients with primary aldosteronism. *World J Urol.* 2017; 35:1577-1583.

**Wu V.C., 2011**

- Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, Chu TS, Chang HW, Lin CY, Tsai CT, Lin LY, Chueh SC, Kao TW, Chen YM, Chiang WC, Tsai TJ, Ho YL, Lin SL, Wang WJ, Wu KD; TAIPAI Study Group. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. *J Hypertens.* 2011; 29:1778-1786.



<b>Study</b>	<b>Parameters of matching</b>
Catena C., 2007	Age, sex, BMI, duration of hypertension
Freel M., 2012	Age, sex, blood pressure, duration of hypertension
Galetta F., 2009	Blood pressure, duration of hypertension
Halimi J., 1995	Age, BMI, mean arterial pressure, renal function, known duration of hypertension
Jiang Y., 2016	Sex, age
Liu G., 2014	Age, sex, blood pressure, duration of hypertension
Muiesan M.L., 2008	Age, sex, blood pressure
Mulatero P., 2013	Age, sex, blood pressure, duration of hypertension, BMI, smoking habits, type 2 diabetes mellitus
Pimenta E., 2011	Age, sex, duration of hypertension, and 24-h systolic and diastolic blood pressure
Reincke M., 2009	Age, sex, BMI
Ribstein J., 2005	Age, sex, BMI, duration of hypertension
Savard S., 2013	Age, sex, blood pressure
Sechi L.A., 2009	Age, sex, BMI, duration of hypertension
Somloova Z., 2010	Age
Takeda R., 1995	Age, sex
Turchi F., 2014	Age, gender, duration of hypertension


**Table S1.** Parameters chosen for clinical matching of patients affected by PA with non-PA hypertensive patients across the studies. BMI = body mass index

<b>Parameter</b>	<b>Primary aldosteronism (n of patients)</b>	<b>Non-primary aldosteronism (n of patients)</b>
Total number of studies (patients)	44 (4,467)	35 (8,234)
Age (years)	50.0 [48.7-52.0] (4,214)	51.0 [49.4-55.5] (7,992)
Female gender (%)	45.9 [36.4-53.8] (4,374)	44.3 [35.8-53.0] (7,744)
BMI (Kg/m <sup>2</sup> )	27.1 [24.4-28.5] (4,188)	26.8 [25.1-28.4] (7,992)
Duration of hypertension (years)	8.5 [7.2-10.0] (3,300)	6.8 [5.6-8.5] (6,476)
SBP (mmHg)	153 [150-163] (4,467)	150 [145-157] (8,216)
DBP (mmHg)	94 [90-97] (4,467)	92 [87-95] (8,216)
Plasma K <sup>+</sup> (mmoL/L)	3.5 [3.1-3.7] (4,164)	4.1 [3.9-4.2] (7,554)
Plasma aldosterone (ng/dL)	31.0 [26.2-41.7] (3,977)	15.4 [11.3-18.4] (6,755)
PRA (ng/ml/h)	0.3 [0.2-0.5] (2,876)	1.6 [1.2-2.3] (4,512)
DRC (mU/L)	4.9 [4.4-5.3] (637)	10.9 [10.2-28.4] (1,764)
Diabetes mellitus (%)	15.7 [6.5-24.3] (2,795)	10.5 [4.8-15.0] (5,832)
Duration of follow-up after PA treatment (months)	12 [6-24] (1,096)	n.app.

**Table S2.** Clinical and biochemical parameters of the included patients. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; PRA = plasma renin activity; DRC = direct renin concentration; n.app=not applicable

Study	Method to estimate or measure GFR
Catena C., 2007	24h creatinine clearance normalized for body surface area
Chiang W.F., 2013	Abbreviated MDRD formula <sup>1</sup>
Florczak E., 2013	n.a.
Fourkiotis V., 2013	Abbreviated MDRD formula <sup>1</sup>
Freel M., 2012	24h creatinine clearance
Iwakura Y., 2014	$194 \times \text{serum creatinine}^{-1.094} \times \text{age}^{-0.287} (\times 0.739 \text{ women})^2$
Iwakura Y., 2016	$194 \times \text{serum creatinine}^{-1.094} \times \text{age}^{-0.287} (\times 0.739 \text{ women})^2$
Kimura G., 1987	n.a.
Kimura G., 1996	Standard clearance techniques using para-amino hippurate and endogenous creatinine
Kobayashi H., 2017	n.a.
Kramers B.J., 2017	CKD-EPI <sup>3</sup>
Liu G., 2014	Abbreviated MDRD formula <sup>1</sup>
Luo Q., 2015	Abbreviated MDRD formula <sup>1</sup>
Monticone S., 2017	Abbreviated MDRD formula <sup>1</sup>
Muiesan M.L., 2008	Abbreviated MDRD formula <sup>1</sup>
Mulatero P., 2013	Cockcroft- Gault formula <sup>4</sup>
Murase K., 2013	n.a.
Murata M., 2017	n.a.
Park K.S., 2017	n.a.
Pimenta E., 2011 (1)	24h creatinine clearance
Pimenta E., 2011 (2)	24h creatinine clearance
Pilz S., 2014	Abbreviated MDRD formula <sup>1</sup>
Reincke M., 2009	Abbreviated MDRD formula <sup>1</sup>
Ribstein J., 2005	Urinary clearance of technetium-labeled diethylene triaminopentaacetic acid ( <sup>99m</sup> Tc-DTPA)
Rosa J., 2012	Creatinine clearance
Rossi G.P., 2006	Abbreviated MDRD formula <sup>1</sup>
Savard S., 2013	Abbreviated MDRD formula <sup>1</sup>
Sechi L.A., 2009	24h creatinine clearance normalized for body surface area
Tanase-Nakao K., 2014	$194 \times \text{Serum creatinine}^{-1.094} \times \text{Age}^{-0.287} \times 0.739 \text{ (if female)}^2$
Utsumi T., 2017	$194 \times \text{Serum creatinine}^{-1.094} \times \text{Age}^{-0.287} \times 0.739 \text{ (if female)}^2$
Wu V.C., 2011	Abbreviated MDRD formula <sup>1</sup>


**Table S3.** Criteria adopted to evaluate glomerular filtration rate (GFR) across the included studies. MDRD = modification of diet in renal disease; CKD-EPI = chronic kidney disease epidemiology collaboration; n.a.= not available.




**Figure S1.** Forest plot of serum creatinine ( $\mu\text{mol/L}$ ) in patients affected by PA and non-PA hypertensive patients. Central squares of each horizontal line represent the mean difference for each study. Horizontal lines indicate the range of the 95% confidence interval and the vertical line at zero indicates no difference between groups.




of 1.0 (which indicates no differences in the odds ratio between patients with PA and patients with EH).




**Figure S5.** Forest plot of uAC ratio in patients with PA and non-PA hypertensive patients. Central squares of each horizontal line represent standard mean difference for each study. Horizontal lines indicate the range of the 95% confidence interval and the vertical line at zero indicates no difference between groups.




**Figure S6.** Funnel plot analysis for serum creatinine in patients affected by PA compared with non-PA hypertensive patients. The plots represent the visual graphical assessment of publication bias.



**Figure S7.** Funnel plot analysis for GFR in patients affected by PA compared with non-PA hypertensive patients. The plots represent the visual graphical assessment of publication bias.




**Figure S8.** Funnel plot analysis for quantitative albuminuria in patients affected by PA compared with non-PA hypertensive patients. The plots represent the visual graphical assessment of publication bias.




**Figure S9.** Funnel plot analysis for uAC ratio in patients affected by PA compared with hypertensive non-PA patients. The plots represent the visual graphical assessment of publication bias.







**Figure S10.** Meta-regression analysis for the prevalence of patients with diabetes on mean difference in GFR between patients affected by PA and non-PA patients, showing that the covariate did not impact significantly on the results (beta -0.011 [-0.163; 0.142])




**Figure S11.** Meta-regression analysis for duration of hypertension on mean difference in GFR between patients affected by PA and patients affected by non-PA, showing that the covariate did not impact significantly the results (beta -0.154 [-1.224; 0.916]).



**Figure S12.** Forest plot of serum creatinine in patients affected by PA before and after specific treatment (either adrenalectomy or medical treatment). Central squares of each horizontal line represent the mean difference for each study. Horizontal lines indicate the range of the 95% confidence interval and the vertical line at zero indicates no difference between groups.



**Figure S13.** Forest plot of uACR in patients affected by PA before and after specific treatment (either adrenalectomy or medical treatment). Central squares of each horizontal line represent the mean difference for each study. Horizontal lines indicate the range of the 95% confidence interval and the vertical line at zero indicates no difference between groups.



**Figure S14.** Qualitative evaluation of studies and risk of bias.